- Home
- LUCD vs OCCI Comparison
LUCD vs OCCI Comparison
Compare LUCD & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LUCD | OCCI |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 135.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LUCD | OCCI |
|---|---|---|
| Price | $1.01 | $5.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.88 | N/A |
| AVG Volume (30 Days) | ★ 646.2K | 115.8K |
| Earning Date | 11-12-2025 | 12-11-2023 |
| Dividend Yield | N/A | ★ 24.32% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,399,000.00 | N/A |
| Revenue This Year | $13.30 | N/A |
| Revenue Next Year | $155.58 | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.01 | N/A |
| 52 Week Low | $0.75 | $5.47 |
| 52 Week High | $1.80 | $10.15 |
Technical Indicators
Market Signals| Indicator | LUCD | OCCI |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 56.92 |
| Support Level | $1.00 | $4.31 |
| Resistance Level | $1.10 | $5.04 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 7.20 | 97.26 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.